Effect of simvastatin on coronary heart disease in patients with type 2 diabetes serum amyloid protein A of.docVIP

 PAGE \* MERGEFORMAT 10 Effect of simvastatin on coronary heart disease in patients with type 2 diabetes serum amyloid protein A of Of: Xu Wei, Hong Bing, Xu Xiaowen, Wei Yu M [Abstract] Objective of simvastatin on coronary heart disease in patients with type 2 diabetes mellitus serum amyloid A (A-SAA). Methods in patients with type 2 diabetes without coronary heart disease in 16 cases; patients with type 2 diabetes, coronary heart disease, 34 cases CHD group was divided into 16 cases of non-treatment group, simvastatin, simvastatin treatment of 18 cases., respectively, for 12 weeks, before and after treatment were detected in the blood biochemical and A-SAA and other indicators. results in patients with type 2 diabetes, coronary heart disease The A-SAA levels higher than those without CHD; 3 groups after 12 weeks of treatment in patients with triglyceride (TG), total cholesterol (TC) and SAA were higher than those before treatment (P lt;0.05), high density lipoprotein cholesterol (HDL-c) was significantly higher (P lt;0.01). Conclusion simvastatin reduced TC, HDL increased, but also by reducing the A-SAA levels to play its role against atherosclerosis. [Keywords:] acute-phase serum amyloid A; 2 diabetes mellitus; coronary heart disease; simvastatin Abstract: Objective To investigate the effect of simvastatin on the acute phase serum amyloid protein A (A-SAA) in patients with coronary disease and type 2 diabetes mellitus. Methods The subjects included 16 patients with type 2 diabetes mellitus but with no coronary disease ( group A) and 34 patients complicated with both type 2 diabetes mellitus and coronary disease, who were further divided into non-simvastatin treatment group (group B, n = 16) and simvastatin treatment group (group C, n = 18). All the patients underwent treatment for 12 weeks and their levels of plasma lipids and A-SAA were measured before and after the treatment. Results At the end of the treatment, the A-SAA levels in groups B and